A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity medications. The study analyzed health records of over 40,000 adults with AUD and either type 2 diabetes or obesity, showing a 22-32% reduction in hospitalization risk. Researchers used advanced methods to mimic randomized trials but caution that further clinical trials are needed to confirm causality. These findings suggest GLP-1 receptor agonists could play a role in reducing alcohol-related harm, highlighting a potential new avenue for treatment.
The NXG Cushing Midstream Energy Fund (SRV) is recommended as a buy due to its well-supported distributions from recent net realized gains and net asset value (NAV) growth. The fund offers a high yield of 12.5%, recently increased by 11%, supported b...
Gold has recently broken out of the price channel that had kept it stable since summer, sparking a rally that is also lifting silver and mining stocks. This movement is significant as gold and bonds are highly sensitive indicators of market imbalance...
Legendary short-seller Jim Chanos highlights a significant $80 billion arbitrage opportunity involving Strategy (MSTR) and its Bitcoin assets. Strategy holds about 847,363 Bitcoins valued at roughly $54 billion, but the stock market values MSTR subst...
Frasers Group PLC has increased its ownership in German fashion brand Hugo Boss to 47.89% following the close of its voluntary takeover offer. The company secured valid acceptances for over 12 million shares, representing about 17.62% of Hugo Boss's ...
Bitcoin climbed to around $64,262, up 1.2% in 24 hours, staying within its $60,000-$66,000 range amid mixed market moves. Venice Token led top 100 gainers with a 12.5% rise, while some altcoins like Worldcoin and Filecoin fell sharply. Bitcoin's mome...
